Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment‐resistant depression
Giovanni Martinotti, Bernardo Dell’Osso, Giorgio Di Lorenzo, et al.
Bipolar Disorders (2023) Vol. 25, Iss. 3, pp. 233-244
Open Access | Times Cited: 50

Showing 26-50 of 50 citing articles:

Intravenous (IV) ketamine versus intranasal esketamine for depression– Advantage IV ketamine?
Balwinder Singh, Simon Kung, Jennifer L. Vande Voort
Journal of Affective Disorders (2024) Vol. 356, pp. 564-567
Closed Access | Times Cited: 3
Early effects predict trajectories of response to esketamine in treatment-resistant depression
Isaure Estrade, Anne‐Cécile Petit, Vincent Sylvestre, et al.
Journal of Affective Disorders (2023) Vol. 342, pp. 166-176
Open Access | Times Cited: 8
Short-term ketamine use in bipolar depression: a review of the evidence for short-term treatment management
Alina Wilkowska, Wiesław Jerzy Cubała
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 8
Ketamine for bipolar depression: an updated systematic review
Farhan Fancy, Sipan Haikazian, Danica E. Johnson, et al.
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 7
The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis
S. Danielle, Nicholas Kleine, Kayla M. Teopiz, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 1, pp. 5-14
Closed Access | Times Cited: 2
Comparing the adverse effects of ketamine and esketamine between genders using FAERS data
Xinxia Yang, Dongdong Chen
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Use of Esketamine Nasal Spray in Patients with Treatment‐Resistant Depression in Routine Practice: A Real‐World French Study
Ludovic Samalin, Lila Mékaoui, Maud Rothärmel, et al.
Depression and Anxiety (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 2
Advances in the management of bipolar disorder in children and adolescents: an update on the literature
Andrea Amerio, Gabriele Arduino, Fabio Fesce, et al.
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 10, pp. 1011-1024
Closed Access | Times Cited: 2
Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment
Luís Gutiérrez-Rojas, Júlia Vendrell-Serres, Josep Antoni Ramos‐Quiroga, et al.
Journal of Psychopharmacology (2024)
Closed Access | Times Cited: 2
Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study
Giacomo d’Andrea, Andrea Miuli, Mauro Pettorruso, et al.
Journal of Affective Disorders (2024) Vol. 367, pp. 583-588
Closed Access | Times Cited: 2
Exploring the potential of Esketamine in the treatment of bipolar depression
Bernardo Dell’Osso, Giovanni Martinotti
European Neuropsychopharmacology (2023) Vol. 77, pp. 21-23
Closed Access | Times Cited: 5
An Update on the Efficacy of Single and Serial Intravenous Ketamine Infusions and Esketamine for Bipolar Depression: A Systematic Review and Meta-Analysis
Nicolás A. Núñez, Boney Joseph, Rakesh Kumar, et al.
Brain Sciences (2023) Vol. 13, Iss. 12, pp. 1672-1672
Open Access | Times Cited: 5
Treatment of bipolar depression: clinical practice vs. adherence to guidelines—data from a Bavarian drug surveillance project
Paul Kriner, Peter Brieger, Oliver Pogarell, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 1
Overcoming treatment-resistant depression with machine-learning based tools: a study protocol combining EEG and clinical data to personalize glutamatergic and brain stimulation interventions (SelecTool Project)
Mauro Pettorruso, Giorgio Di Lorenzo, Beatrice Benatti, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 1
Intravenous patient-controlled analgesia with esketamine improves early depressive symptoms in patients with postherpetic neuralgia: a single-center retrospective cohort study
Ling Qiu, Xuhui Chen, Jia Fu, et al.
BMC Psychiatry (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Esketamine nasal spray in severe bipolar depression with borderline personality disorder and history of multiple substance abuse: A case report
Renato de Filippis, Pasquale De Fazio
Bipolar Disorders (2023) Vol. 25, Iss. 6, pp. 524-526
Closed Access | Times Cited: 2
Intranasal esketamine as tool for rapid cycling bipolar disorder: A case report of successful mood stabilization
Giacomo d’Andrea, Ornella Di Marco, Francesco Maria Semeraro, et al.
Psychiatry Research Case Reports (2023) Vol. 2, Iss. 2, pp. 100188-100188
Open Access | Times Cited: 1
Evaluating passive physiological data collection during Spravato treatment
Todd M. Solomon, Matus Hajduk, Martin Majernik, et al.
Frontiers in Digital Health (2023) Vol. 5
Open Access | Times Cited: 1
Intravenous Patient-Controlled Analgesia with Esketamine Improves Early Depressive Symptoms in Patients with Postherpetic Neuralgia: A Single-Center Retrospective Cohort Study
Ling Qiu, Xuhui Chen, Fu Jia, et al.
Research Square (Research Square) (2024)
Open Access
Intranasal esketamine and manic symptoms: A disproportionality analysis in EudraVigilance
Vladimir Akhrimenko, Montserrat García, C Aguirre, et al.
European Neuropsychopharmacology (2024) Vol. 86, pp. 44-45
Closed Access
Outpatient Management of Bipolar Disorder in Older Adults
Brian G. Donley, Erica C. Garcia-Pittman
Current Psychiatry Reports (2024)
Closed Access
Repeated Intravenous Infusions of Esketamine in Inpatients with Bipolar Depression: A Retrospective Real-World Study
Norah J. Shire, Michael Ioannou, Örjan Falk, et al.
Journal of Affective Disorders Reports (2024) Vol. 19, pp. 100870-100870
Open Access
Giovanni Martinotti: Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine and bipolar × unipolar treatment resistant depression
Maria Ana Sousa Gonçalves, Thalles Rodrigues Alves Leite, Everaldo de Alcântara Brandão Júnior, et al.
Bipolar Disorders (2023) Vol. 25, Iss. 5, pp. 429-430
Closed Access
A synopsis of multitarget therapeutic effects of anesthetics on depression
Guowei Wu, Hongwei Xu
European Journal of Pharmacology (2023) Vol. 957, pp. 176032-176032
Closed Access
A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics
Lien Wang, Xiaowei Chen, Xiaojing Gu, et al.
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 2857-2870
Open Access
Previous Page - Page 2

Scroll to top